Suzhou Jiecheng Medical Technology Co., Ltd. was founded in September 2009 and is headquartered in Suzhou Industrial Park. As a national-level high-tech enterprise, it specializes in the R&D, production and sales of high-end cardiovascular medical devices. The company’s R&D team was formed by cardiac surgeon Dr. Zhang Ji together with experts from China and abroad.
Its core product is the J-Valve Precision Positioning Heart Valve Implantation System, a global first. The system enables minimally invasive treatment of aortic valve diseases, features autonomous positioning, and solves the international technical challenge of treating pure regurgitation cases without calcification.
In April 2017, the company’s self-developed transcatheter biological heart valve became one of the first domestically approved TAVR products in China. In February 2022, it was fully acquired by Genesis Medtech and became the Structural Heart Disease Business Unit.
